Table 3.

Genetic biomarkers as potential predictors of a complete response to endoscopic therapy.

a. Whole cohort (N=181)
Variable	HR	95% CI	P value
Normal FISH result	1.48	1.03-2.14	0.035
Barrett’s segment length, cm	0.84	0.78-0.90	<0.001
BMI	0.94	0.90-0.98	0.002
P16 loss	0.97	0.64-1.48	0.90
Barrett’s segment length, cm	0.83	0.77-0.88	<0.001
BMI	0.94	0.90-0.98	0.005
Single locus gain	0.67	0.43-1.06	0.09
Barrett’s segment length, cm	0.83	0.77-0.88	<0.001
BMI	0.94	0.90-0.98	0.003
Multiple gains	0.60	0.41-0.86	0.006
Barrett’s segment length, cm	0.83	0.78-0.89	<0.001
BMI	0.94	0.90-0.98	0.003
b. Patients undergoing RFA (N=66)
Variable	HR	95% CI	P value
Normal FISH result	1.23	0.62-2.44	0.55
Barrett’s segment length, cm	0.91	0.82-1.02	0.10
P16 loss	0.87	0.45-1.69	0.68
Barrett’s segment length, cm	0.91	0.81-1.02	0.09
Single locus gain	1.25	0.63-2.48	0.53
Barrett’s segment length, cm	0.90	0.81-1.00	0.06
Multiple gains	0.58	0.31-1.09	0.09
Barrett’s segment length, cm	0.92	0.83-1.03	0.14

HR, hazard ratio; FISH, fluorescence in situ hybridization

A complete response was defined as the absence of dysplasia and/or carcinoma after 2 serial endoscopies with Seattle protocol biopsies.

^*Values were calculated with the use of multivariable Cox regression analysis.